Welcome!

News Feed Item

Research and Development Forecast of China Heparin Industry, 2013-2017

NEW YORK, Jan. 21, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Research and Development Forecast of China Heparin Industry, 2013-2017
http://www.reportlinker.com/p01957801/Research-and-Development-Forecast-of-China-Heparin-Industry-2013-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Research_and_Development

Research and Development Forecast of China Heparin Industry, 2013-2017 mainly analyzes the global and domestic market status quo of heparin industry, development conditions of heparin upstream and downstream industry, the supply and demand of major products, competitive pattern and business performance of domestic major enterprises; in the meanwhile, it makes the analysis and forecast of the future development of the heparin industry, offering the decisive reference for enterprises to know and invest the heparin industry.

The global heparin API manufacturing enterprises are mainly concentrated in the China, Europe and the US; the supply volume of heparin APIs of these three regions accounts for more than 95% of the global supply volume; the supply volume of heparin AIPs in China ranks the world first and accounts for more than 50% of the global supply volume.

According to the statistics of China Customs, since 2007, the export amount of China's heparin products has been rising greatly for a fourth consecutive year; in 2011, under the affection of depressed international market and the improvement of heparin export standards, the export volume and amount of China's heparin products had the obvious decline; in the year of 2012 and 2013, the decline trend of the export volume of heparin products slowed, but the export amount still had a certain decline because of the price.

At present, China has totally 22 heparin API manufacturing enterprises that have passed the approval of China Food and Drug Administration, but there are less than 10 manufacturers that have engaged in the actual production; in addition, there are 500 to 1,000 companies of heparin crude products, which form the high domestic heparin API production concentration ratio; the production capacity is mainly concentrated in the top five manufacturing enterprises of heparin products with about 80% of market shares totally now. Hepalink has the largest market shares of about 40% in the domestic market; the other major enterprises include Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Changzhou Qianhong Bio-pharma Co., Ltd., Yantai Dongcheng Biochemicals Co., Ltd. and Qingdao Jiulong Biomedicine Co., Ltd., while the downstream resource are inadequate.
1. Industry Overview of Heparin
1.1 Definition and Classification
1.1.1 Definition
1.1.2 Classification
1.2 Industrial Chain

2. China's Heparin Industry Development Environment
2.1 China's Economic Development Environment
2.2 Related Policies and Standards
2.2.1 Related Policies and Regulations
2.2.2 Related Standards

3. Development Overview of China's Heparin API (Active Pharmaceutical Ingredient) Industry
3.1 Development Overview of Global Heparin Industry
3.2 Status Quo of China's Heparin API Industry
3.2.1 Market Status Quo
3.2.2 Market Supply and Demand
3.3 Imports and Exports
3.4 Competitive Pattern

4. Development Overview of China's Heparin Upstream and Downstream Industry
4.1 Upstream Industry
4.2 Downstream Industry
4.2.1 Low Molecule Weight (LMW) Heparin Preparations
4.2.2 Unfractionated Heparin Preparations

5. China's Major Heparin Manufacturing Enterprises
5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd. (Hepalink)
5.1.1 Company Profile
5.1.2 Business Performance
5.1.3 Research & Development and Investment
5.1.4 Development Prospects
5.2 Changzhou Qianhong Bio-pharma Co., Ltd.

5.2.1 Company Profile
5.2.2 Business Performance
5.2.3 Research & Development and Investment
5.2.4 Development Prospects
5.3 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
5.3.1 Company Profile
5.3.2 Business Performance
5.3.3 Research & Development and Investment
5.3.4 Development Prospects
5.4 Yantai Dongcheng Biochemicals Co., Ltd.
5.4.1 Company Profile
5.4.2 Business Performance
5.4.3 Research & Development and Investment
5.4.4 Development Prospects
5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd.
5.5.1 Company Profile
5.5.2 Business Performance
5.5.3 Research & Development and Investment
5.5.4 Development Prospects
5.6 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
5.6.1 Company Profile
5.6.2 Research & Development
5.6.3 Development Prospects
5.7 Qingdao Jiulong Biomedicine Co., Ltd.

6. Investment Analysis of Heparin Industry
6.1 Investment Risks
6.1.1 Industry Risk
6.1.2 Intensifying Market Competition
6.1.3 Loss of Technical Personnel
6.1.4 Downward Product Price
6.1.5 Raw Material Price Fluctuation
6.1.6 Exchange Rate Fluctuation
6.2 Investment Suggestions
6.2.1 Investing the Scale Enterprises
6.2.2 Paying Attention to Brand Building
6.2.3 Doing Well Human Resource Management
6.2.4 Developing New Products and Being Diversified
6.2.5 Competition Alliance

7. Development Trends and Forecast of Heparin Industry
7.1 Development Trends
7.2 Market Scale Forecast of Heparin Products

To order this report: Research and Development Forecast of China Heparin Industry, 2013-2017
http://www.reportlinker.com/p01957801/Research-and-Development-Forecast-of-China-Heparin-Industry-2013-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Research_and_Development

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Behera Rasananda is a technologist, a leader, a key note speaker has more than 20 years experience in across Government, Financial, Heath Care and Insurance Verticals. Mr. Behera has vast experience in Enterprise Cloud and Big Data solutions and Enterprise Architecture. Currently he works closely for Government Solutions on Enterprise Cloud for Federal Government Agency. Scientist Behera managed and partner with clients to make complete end to end solution and Migration to cloud both private sec...
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, r...
They say multi-cloud is coming, but organizations are leveraging multiple clouds already. According to a study by 451 Research, only 21% of organizations were using a single cloud. If you've found yourself unprepared for the barrage of cloud services introduced in your organization, you will need to change your approach to engaging with the business and engaging with vendors. Look at technologies that are on the way and work with the internal players involved to have a plan in place when the ine...
Excitement and interest in APIs has skyrocketed in recent years. However, if you ask a room full of IT professionals "What is an API", you will get a wide array of answers. There exists a wide knowledge gap between API experts and those that have a general idea of what they are, but are unsure of what they have been for in the past, what they look like now, and how they can be used to expand your business in the future. In this session John will cover what the history of APIs, what an API looks ...
The now mainstream platform changes stemming from the first Internet boom brought many changes but didn’t really change the basic relationship between servers and the applications running on them. In fact, that was sort of the point. In his session at 18th Cloud Expo, Gordon Haff, senior cloud strategy marketing and evangelism manager at Red Hat, will discuss how today’s workloads require a new model and a new platform for development and execution. The platform must handle a wide range of rec...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
Bill Schmarzo, Tech Chair of "Big Data | Analytics" of upcoming CloudEXPO | DXWorldEXPO New York (November 12-13, 2018, New York City) today announced the outline and schedule of the track. "The track has been designed in experience/degree order," said Schmarzo. "So, that folks who attend the entire track can leave the conference with some of the skills necessary to get their work done when they get back to their offices. It actually ties back to some work that I'm doing at the University of ...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
DevOps with IBMz? You heard right. Maybe you're wondering what a developer can do to speed up the entire development cycle--coding, testing, source code management, and deployment-? In this session you will learn about how to integrate z application assets into a DevOps pipeline using familiar tools like Jenkins and UrbanCode Deploy, plus z/OSMF workflows, all of which can increase deployment speeds while simultaneously improving reliability. You will also learn how to provision mainframe syste...